Cargando…

Outcomes of allogeneic stem cell transplantation for patients with hematologic diseases ≥60 years old

Hematologic diseases frequently affect people >60 years old, and allogeneic stem cell transplantation (allo-SCT) is a potentially curative treatment for these patients. Although several multicenter studies proposed the risk assessment of allo-SCT for the elderly, they receive different treatments...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shima, Takahiro, Takigawa, Ken, Utsumi, Sae, Yoshino, Teruhiko, Naganuma, Megumi, Minami, Mariko, Hayashi, Masayasu, Matsuo, Yayoi, Kuriyama, Takuro, Eto, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asia-Pacific Blood and Marrow Transplantation Group 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279488/ https://www.ncbi.nlm.nih.gov/pubmed/37342355 http://dx.doi.org/10.31547/bct-2022-018

Ejemplares similares

The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases
por: Yoshida, Shuro, et al.
Publicado: (2018)

Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome
por: Hosoi, Hiroki, et al.
Publicado: (2018)

Prospective studies of allogeneic hema topoietic stem cell transplantation for adult T-cell leukemia-lymphoma
por: Cho, Ilseung, et al.
Publicado: (2015)

Allogeneic stem cell transplantation for mantle cell lymphoma—update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74)
por: Krüger, William H., et al.
Publicado: (2021)

Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL
por: Yuda, Junichiro, et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders
por: Mahmoud, Hossam K., et al.
Publicado: (2015)

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies
por: Zahid, Mohammad Faizan, et al.
Publicado: (2014)

Facile Multiple Alkylations of C(60) Fullerene
por: Miwa, Kazuhira, et al.
Publicado: (2022)

Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
por: Pavletic, ZS, et al.
Publicado: (1998)

Rapid cardiovascular aging following allogeneic hematopoietic cell transplantation for hematological malignancy
por: Dillon, Hayley T., et al.
Publicado: (2022)

Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies
por: Fukuhara, Suguru, et al.
Publicado: (2022)

Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy
por: Araie, Hiroaki, et al.
Publicado: (2023)

Late Toxicity of a Novel Allogeneic Stem Cell Transplant Using Single Fraction Total Body Irradiation for Hematologic Malignancies in Children
por: Madden, Lisa M., et al.
Publicado: (2015)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

Severe pulmonary alveolar proteinosis with respiratory failure treated by intrapulmonary percussive ventilation
por: Tashiro, Takahiro, et al.
Publicado: (2020)

Implication of Ivabradine in Patients with Acute Heart Failure and Sinus Tachycardia Following Allogenic Hematopoietic Cell Transplantation
por: Henmi, Heisuke, et al.
Publicado: (2022)

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology
por: Xu, Lanping, et al.
Publicado: (2018)

2696. Breakthrough Toxoplasmosis While on Atovaquone Prophylaxis Following Allogeneic Hematologic Stem Cell Transplantation
por: Chueng, Teresa A, et al.
Publicado: (2019)

Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies
por: Bi, Xia, et al.
Publicado: (2022)

Infectious complications after second allogeneic hematopoietic cell transplant in adult patients with hematological malignancies
por: Maurer, Stephen M., et al.
Publicado: (2022)

Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application
por: Kato, Koji, et al.
Publicado: (2020)

Electrochemical reduction of cationic Li(+)@C(60) to neutral Li(+)@C(60)˙(–): isolation and characterisation of endohedral [60]fulleride
por: Ueno, Hiroshi, et al.
Publicado: (2016)

Clinical Significance of Platelet Count at day +60 After Allogeneic Peripheral Blood Stem Cell Transplantation
por: Kim, Dong Hwan, et al.
Publicado: (2006)

GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
por: Muranushi, Hiroyuki, et al.
Publicado: (2020)

A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
por: Jo, Tomoyasu, et al.
Publicado: (2023)

Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation
por: Deeg, H. Joachim
Publicado: (2022)

Author Correction: A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
por: Jo, Tomoyasu, et al.
Publicado: (2023)

Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
por: Murata, Makoto, et al.
Publicado: (2020)

Clinical Features of Patients With Hematological Malignancies Treated at the Palliative Care Unit
por: Yamane, Hiromichi, et al.
Publicado: (2023)

Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies
por: Paiano, Sandra, et al.
Publicado: (2015)

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
por: Kuruvilla, J., et al.
Publicado: (2022)

Decrease in Social Zeitgebers Is Associated With Worsened Delayed Sleep-Wake Phase Disorder: Findings During the Pandemic in Japan
por: Otsuki, Rei, et al.
Publicado: (2022)

Corrigendum: Decrease in social zeitgebers is associated with worsened delayed sleep-wake phase disorder: findings during the pandemic in Japan
por: Otsuki, Rei, et al.
Publicado: (2023)

828. Do lung co-infections influence outcome in patients with hematological malignancies and culture-documented invasive pulmonary aspergillosis?
por: Matsuo, Takahiro, et al.
Publicado: (2023)

Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study
por: Inamo, Yasuji, et al.
Publicado: (2014)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

The innate immune system in host mice targets cells with allogenic mitochondrial DNA
por: Ishikawa, Kaori, et al.
Publicado: (2010)

CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)—Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
por: Schmidt-Hieber, M., et al.
Publicado: (2016)

Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea
por: Ji, Young Sok, et al.
Publicado: (2023)

Transcriptional regulation of chondrogenesis by coactivator Tip60 via chromatin association with Sox9 and Sox5
por: Hattori, Takako, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_pipr3e9663pj6q7s3srbtebg2k